Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Blood (2025) 146 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2025-4198

Published: 2025

Journal Articles

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation

Dat Ngo, Jose Tinajero, Karamjeet Sandhu, Idoroenyi Amanam, Salman Otoukesh, Shukaib Arslan, Sunmin Park, Haris Ali, Badri Modi, Ryotaro Nakamura, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 7612.

https://doi.org/10.1182/blood-2025-7612

Published: 2025

Journal Articles

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Klara Kim, Dat Ngo, Jose Tinajero, Dongyun Yang, Haoyue Shan, Karamjeet Sandhu, Haris Ali, Salman Otoukesh, Idoroenyi Amanam, Shukaib Arslan, Vaibhav Agrawal, Sunmin Park, Ryotaro Nakamura, Monzr M. Al Malki, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 935.

https://doi.org/10.1182/blood-2025-935

Published: 2025

Journal Articles

Microbiome and cytokine features are associated with graft-versus-host disease incidence in allogeneic hematopoietic cell transplantation patients

Antonio Luiz Cruz Gomes, Natalie Smith, Sally Mokhtari, Jenny Paredes, Jennifer Karmouch, Xinran Qi, Dongyun Yang, Weimin Tsai, Marcel van den Brink, Karamjeet Sandhu, Ryotaro Nakamura, Robert Jenq

Blood (2025) 146 (Supplement 1): 6072.

https://doi.org/10.1182/blood-2025-6072

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

Blood (2025) 146 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2025-2441

Published: 2025

Journal Articles

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Blood (2025) 146 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2025-1684

Published: 2025

Journal Articles

Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel)

Benjamin Simpson, Rehan Hussain, Mohammed Banani, Karamjeet Sandhu, Michael Bishop, Aaron Logan, Ping Wang, William Day, Claire Roddie, Pierre Lao-Sirieix

Blood (2025) 146 (Supplement 1): 33.

https://doi.org/10.1182/blood-2025-33

Published: 2025

Journal Articles

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

Blood (2025) 146 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2025-2396

Published: 2025

Journal Articles

Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis

Salman Otoukesh, Brian Ball, Dongyun Yang, Ketevan Gendzekhadze, Karamjeet Sandhu, Shukaib Arslan, Amanda Blackmon, Pamela Becker, Firoozeh Sahebi, Anna Pawlowska, Monzr M. Al Malki, Michelle Afkhami, Stephen Forman, Guido Marcucci, Vinod Pullarkat, Raju Pillai, Ryotaro Nakamura

Blood (2025) 146 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2025-1431

Published: 2025

Journal Articles

Trial-in-progress: A phase 2 randomized trial of remodeling intestinal microbiota using fecal microbiome transplant (FMT) among recipients of chimeric antigen receptor T cells (CAR T)

Karamjeet Sandhu, Xinran Qi, Sally Mokhtari, Xin-Zi Emily Tang, John Baird, Alexander Khoruts, Elizabeth Budde, Robert Jenq

Blood (2025) 146 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2025-5507

Published: 2025

Journal Articles

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2025-3365

Published: 2025

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Blood (2025) 146 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2025-4305

Published: 2025

Journal Articles

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Blood (2025) 146 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2025-2464

Published: 2025

Journal Articles

Poor nutritional intake prior to allogeneic hematopoietic cell transplantation is associated with higher incidence of lower-gastrointestinal graft-versus-host disease

Natalie Smith, Antonio Luiz Cruz Gomes, Sally Mokhtari, Jennifer Karmouch, Dongyun Yang, Adhithi Rajagopalan, Nune Azaryan, Linda Hang, Claire Chappuis, Adern Yu, Jenny Paredes, Robert Jenq, Ryotaro Nakamura, Karamjeet Sandhu, Marcel van den Brink

Blood (2025) 146 (Supplement 1): 4250.

https://doi.org/10.1182/blood-2025-4250

Published: 2025

Journal Articles

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Blood (2025) 146 (Supplement 1): 818.

https://doi.org/10.1182/blood-2025-818

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Ibrahim Aldoss, Xiuli Wang, Lu Chen, Joo Song, Karamjeet Sandhu, Alan Macias, Neguine Sanani, Baishakhi Barva, Min Guan, Ruby Espinosa, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Guido Marcucci, Elizabeth Budde, Larry Kwak, Stephen Forman

Blood (2025) 146 (Supplement 1): 813.

https://doi.org/10.1182/blood-2025-813

Published: 2025

Journal Articles

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Aaron Logan, Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly

Blood (2025) 146 (Supplement 1): 516.

https://doi.org/10.1182/blood-2025-516

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Blood (2025) 146 (Supplement 1): 2516.

https://doi.org/10.1182/blood-2025-2516

Published: 2025

Journal Articles

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Blood (2025) 146 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2025-2715

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Microbiome and cytokine features are associated with graft-versus-host disease incidence in allogeneic hematopoietic cell transplantation patients

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel)

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis

Trial-in-progress: A phase 2 randomized trial of remodeling intestinal microbiota using fecal microbiome transplant (FMT) among recipients of chimeric antigen receptor T cells (CAR T)

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Poor nutritional intake prior to allogeneic hematopoietic cell transplantation is associated with higher incidence of lower-gastrointestinal graft-versus-host disease

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only